Crossmark

Ultrasensitive bioassaying of HER-2 protein for diagnosis of breast cancer using reduced graphene oxide/chitosan as nanobiocompatible platform

Published Online: 2021-05-01

Published Print: 2021-12

Authors

Nasrollahpour, Hassan

Isildak, Ibrahim

Rashidi, Mohammad-Reza

Hashemi, Esmat Alsadat

Naseri, Abdolhosein

Khalilzadeh, Balal http://orcid.org/0000-0003-2262-6453
Funding

Funding for this research was provided by:

National Institute for Medical Research Development (973631)
License Information

Text and Data Mining valid from 2021-05-01

Version of Record valid from 2021-05-01
More Information

Article History

Received: 10 January 2021

Accepted: 22 April 2021

First Online: 1 May 2021

Declarations

:

: All phases of this study were approved by National Committee for Ethics in Biomedical Research (IR.NIMAD.REC.1397.531). Prior to sampling, all patients were requested to fill informed consent.

: Not applicable.

: The authors declare no competing interest.

Document is current